Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs
Rhea-AI Summary
Orocidin, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced positive efficacy results for its lead periodontitis treatment candidate, QR-01, in a preclinical study with dogs. The 13-day small efficacy study, conducted on beagle dogs with clinically confirmed periodontitis, showed consistent improvements across key clinical endpoints including:
- Gingival Index
- Plaque Index
- Overall periodontal Disease
The treatment was well-tolerated with no adverse side effects reported. The company plans to proceed with a human pilot efficacy study scheduled to begin by the end of 2025.
Positive
- Successful preclinical efficacy results for QR-01 periodontitis treatment
- No adverse side effects reported during treatment period
- Clear pathway to human trials established for late 2025
Negative
- Early-stage preclinical results only, with small sample size
- Human trials not starting for over a year (end of 2025)
News Market Reaction – NORD
In the trading session that priced this news, NORD gained 5.26%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced positive efficacy results for its lead periodontitis candidate, QR-01, in a preclinical study involving dogs diagnosed with periodontitis.
The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis. and demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal Disease. The animals were fasted for a minimum of 8 hours prior to assessment of the efficacy.
Importantly, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period.
“I am pleased to report that all dogs in the study showed encouraging and consistent responses to the treatment. This represents a significant milestone for Orocidin’s lead product, QR-01 and strengthens our confidence as we prepare for the upcoming human pilot efficacy study, planned to begin by the end of 2025,” said Allan Wehnert, CEO & Founder of Orocidin.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
